Many small-molecule anti-cancer therapies are prone to active efflux at the BBB by P-glycoprotein (P-gp; also known as ABCB1) and breast cancer resistance protein (Bcrp; also known as ABCG2), and this can severely limit drug distribution to the brain19,21. The gene discussed is ABCG2; the disease is cancer.